Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study
NCT ID: NCT01857518
Last Updated: 2017-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2013-08-31
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aims of the study are (1) to identify the changes in brain morphometry, white matter microstructure, and functioning, in networks associated with depression features in adolescents, and (2) to assess the effects of treated pathology on brain structure by comparing the neuroimaging measures obtained in adolescents at inclusion with those at follow-up.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis of altered structural integrity of limbic prefrontal pathways emerges from the literature on depression, but it is unknown whether it is also detectable in adolescents with depression. Thus, we aim to investigate WM and GM structure and anatomy, and functional correlates of behavioral responses in depressed adolescents.
40 adolescents with a Major Depressive Episode will be investigated using structural T1 magnetic-resonance imaging and diffusion tensor imaging (DTI), at inclusion and after one-year follow-up. Additionally, they will be investigated with fMRI.
Covariation patterns between neuroimaging and behavioural/clinical variables will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depressed adolescents Group
Adolescents with a major depressive episode diagnosis
-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
* Visit V1: Diagnostic and clinical assessments
* Visit V2: psycho-behavioral assessment and neuroimaging
* Visit V3: Diagnostic and clinical assessments
* Visit V4: psycho-behavioral assessment and neuroimaging
Healthy adolescent control Group
Healthy adolescents recruited from general population
-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
* Visit V1: Diagnostic and clinical assessments
* Visit V2: psycho-behavioral assessment and neuroimaging
* Visit V3: Diagnostic and clinical assessments
* Visit V4: psycho-behavioral assessment and neuroimaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
* Visit V1: Diagnostic and clinical assessments
* Visit V2: psycho-behavioral assessment and neuroimaging
* Visit V3: Diagnostic and clinical assessments
* Visit V4: psycho-behavioral assessment and neuroimaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Teenagers of both sexes, from 15 to 18 years old, without contreindications in magnetic fields
* affiliation to a Social insurance
* Informed consent signed by the holders of the parental rights (a specific information note to the teenager)
* Diagnosis DSM-IV-TR ( 2000 ) of depressive Disorder of the humor without psychotic characteristics. The symptoms will have to be persistent for 3 weeks, in spite of a coverage of support ( 2 consultations).
Exclusion Criteria
* Claustrophobia, Syndrom of post-traumatic stress, Obsessive-compulsive Disorder, Disturb Tricks, Disturbs abuse of substances
* Intrusive disorder of the development, Disturbs hyperactivity deficit of the attention, Disorders of the conducts, Schizophrenia
* Current antidepressant or antipsychotic psychotropic Treatment for more than 15 days in effective doses
* Current somatic pathology, or pregnancy (urinary test of pregnancy in case of doubt)
* Histories of cranial trauma or neurological pathology, or of lower born weight in 800g
* History of electroconvulsivotherapy in the previous 6 months
* Refusal to give his(her) consent or to be revised on one year after inclusion
Healthy adolescents: will be screened to be matched to the patients according to age and sex. They will have no psychiatric diagnosis, and no family history of psychiatric conditions.
15 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CENIR Centre de Neuroimagerie de Recherche, Paris
UNKNOWN
Inserm CEA Research unit U1000 (Neuroimaging in psychiatry)
UNKNOWN
National Research Agency, France
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Centre Hospitalier St Anne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Laure PAILLERE MARTINOT, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cochin Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marie-Laure PAILLERE, MD, PhD
Role: primary
Marie GODARD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D500
Identifier Type: OTHER
Identifier Source: secondary_id
2012-A01466-37
Identifier Type: -
Identifier Source: org_study_id